Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<p>Plasma concentration for copanlisib (BAY 80-6946). Plasma concentration of copanlisib (BAY 80-6946) was measured in samples from nine patients collected on cycle 1 day 15 before infusion (pre-dose) and at 0.5, 1, 2, 4, 6, 8, and 24 hours after infusion. Eight patients received copanlisib 45...

पूर्ण विवरण

में बचाया:

ग्रंथसूची विवरण
मुख्य लेखक:	Andre L. De Souza (22819921) (author)
अन्य लेखक:	Matthew J. Hadfield (22819924) (author), Shaolei Lu (22819927) (author), Dragan J. Golijanin (22819930) (author), Roxanne Wood (22819933) (author), Jeannine Margolis (22819936) (author), Kate Anderson (22819939) (author), Adam J. Olszewski (15129834) (author), Sheldon L. Holder (22819942) (author), Wafik S. El-Deiry (15170575) (author), Rahul R. Aggarwal (15132918) (author), Anthony E. Mega (22819945) (author), Benedito A. Carneiro (15925723) (author)
प्रकाशित:	2025
विषय:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I Clinical Trials Prostate Cancer Small Molecule Agents DNA-reactive agents
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

समान संसाधन